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Edited by Hans EklundAbstract Urate oxidase from Aspergillus ﬂavus catalyzes the
degradation of uric acid to [S]-allantoin through 5-hydroxyisou-
rate as a metastable intermediate. The second degradation step is
thought either catalyzed by another speciﬁc enzyme, or sponta-
neous. The structure of the enzyme was known at high resolution
by X-ray diﬀraction of I222 crystals complexed with a purine-
type inhibitor (8-azaxanthin). Analyzing the X-ray structure of
urate oxidase treated with an excess of urate, the natural sub-
strate, shows unexpectedly that the active site recaptures [S]-
allantoin from the racemic end product of a second degradation
step.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Urate oxidase (uricase; EC 1.7.3.3; or UOX) is a 135 kDa
tetrameric enzyme of therapeutic interest implicated in the
catalysed degradation of uric acid (Scheme 1). It catalyzes
the ﬁrst step of the degradation of uric acid 1 to 5-hydroxyiso-
urate (5-HIU) 2. The second degradation step leads to [S]-
allantoin 3 (or [S]-ALN). UOX from Aspergillus ﬂavus gene,
cloned in a Saccharomyces cerevisiae strain, is produced by Sa-
noﬁ-Aventis according to a patented process.
The ﬁrst three-dimensional structure of extracted UOX was
solved at a resolution of 2.05 A˚ in complex with 8-azaxanthin
(8-AZA), a stabilizing inhibitor [1] in the I222 orthorhombic
form. Following this ﬁrst report and the preparation of recom-
binant UOX, several more accurate structures, in complex
with 9-methyl urate or oxonate became available [2]. High-dif-
fraction properties of the resulting diamond-shaped I222 crys-Abbreviations: UOX, urate oxidase; 8-AZA, 8-azaxanthin; [S]-ALN,
[S]-allantoin; 5-HIU, 5-hydroxyisourate; RMSD, root mean squares
deviation
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doi:10.1016/j.febslet.2006.03.007tals conﬁrmed that these molecules were good analogues.
Moreover, the structure of the ligand-free enzyme solved from
a monoclinic form (P21) was also described as well as other
polymorphs using the less analogous uracil or guanine as
ligands [3] but diﬀracting at lower resolution. All these
purine-type inhibitors share the same –NH(3)–CO(2)–NH(1)–
CO(6)– motif in their six-membered ring. Other close com-
pounds like cafein, theobromin or theophyllin whose NH are
methylated, do not interact with UOX [4]. When ligand-free
UOX crystals are soaked in a urate-containing solution, they
immediately crack and dissolve, as a result of conformational
changes during the in situ catalytic reaction. To get more infor-
mation about the catalytic pathway and about the end of the
reaction, the enzyme was ﬁrst set to react in solution with ur-
ate, then set to crystallize afterwards. In all cases, the complex
leads to the formation of the high resolution I222 orthorhom-
bic crystals, an indication that stabilization occurs within the
active site at the end of the reaction prior to crystallization.
The present study aims at characterizing the content of the
protein at that time.2. Materials and methods
2.1. Crystallizations
Puriﬁed recombinant UOX from A. ﬂavus, expressed in S. cerevisiae,
was supplied by Sanoﬁ-Aventis. All additives and chemicals used in
this study (uric acid, polyethyleneglycol, etc.) were purchased from
Sigma–Aldrich. The enzyme was incubated at a concentration of
15 mg/mL at pH 8.5 with an excess of uric acid (0.5–2 mg/mL). The
solution was immediately set to crystallize following identical crystal
growth conditions as previously described using the sitting-drop vapor
diﬀusion method at room temperature [5]. 5–10 mg/mL protein in
50 mM Tris/HCl pH 8.5 in the presence of 5–8% w/v PEG 8000 and
NaCl 0.05 M, led to orthorhombic crystals within 24–48 h. They grow
to their full extension (0.6 mm) within a week.2.2. X-ray data collection and data processing
X-ray data collections were carried out at the ESRF BM14 beam-
line, at a wavelength of 0.972 A˚ and operating in a 16 bunch mode,
using a MAR CCD detector; temperature was set to 277 K. Data were
integrated by DENZO and scaled independently using SCALEPACK,
both software are parts of the HKL package [6]. Cell parameters were
reﬁned by the post-reﬁnement technique implemented in SCALE-
PACK. The merged intensity data were converted to structure-factor
amplitudes by TRUNCATE [7] and put on an approximate absolute
scale using the scale factor taken from a Wilson plot computed with
data in the resolution range of 5 A˚ – dmin (see statistics in Table 1).blished by Elsevier B.V. All rights reserved.
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The structure was solved by Fourier synthesis using the calculated
phases derived from the isomorphous structure taken from the Protein
Data Bank (code 1R51 or 1R4S) after removing all the water mole-
cules and the ligand.Table 1
Data collection and reﬁnements statistics
Data collection
Space group I222
Parameters (A˚)
a 80.36
b 96.09
c 105.37
Number of unique reﬂections 39454
Data redundancy 4.8
All data (10.9–1.75 A˚)
Rsym (%) 6.4
Mean I/r(I) 18.7
Overall completeness (%) 98.1
Highest resolution shell (2.1–2.0 A˚)
Rsym (%) 28.7
Mean I/r(I) 5.1
Completeness (%) 97.6
Reﬁnements (SHELXL)
Number of atoms
UOX 2384
[S]-ALN 11
Solvent (H2O) 168
Resolution range (A˚) 10–1.76
Number of parameters/restraints 10259/9887
R factor (%), for 4r observed data (number) 19.1 (33270)
R factor (%), for all data (number) 20.8 (39227)
Free R factor (%) for 7% of obs. data (number) 23.0 (2758)
Value
Mean isotropic ÆBæ values (A˚2)
Main chain 18.7
Side chain 25.6
Water molecules 35.9
[S]-allantoin 28.0
Residuals in ﬁnal Fourier map (min/max) (e) 0.25/+0.40
RMS deviations Number Target/value
1–2 Bond length (A˚) 2451 0.03/0.034
1–3 Bond-distance angles (A˚) 3321 0.08/0.077
Planes (A˚) 790 0.4/0.35
Non-zero chiral volumes (A˚3) 369 0.1/0.045The structure reﬁnements were carried out with the program
SHELXL [8]. Throughout the course of reﬁnements, 7% of the data
was left out for cross validation (R-free).
The ﬁrst SIGMAA 2|Fo–Fc| map revealed the presence of an elon-
gated density in the active site accurate enough to be readily shaped
as [S]-allantoin. Subsequent maps were checked to remove signiﬁcant
errors in the model, and manual rebuildings were performed using
the program O [9]. Alternations of rounds of positional plus restrained
B-factor reﬁnements followed by manual rebuilding using O were per-
formed until model completion, including successive locations and
reﬁnements of water molecules. Final statistics on the model parameter
reﬁnements are given in Table 1. Coordinates are deposited with the
Protein Data Bank (PDB code: 2FXL). Fig. 1 typically represents a
2Fo–Fc map around the ligand, located in the active site.3. Results and discussion
Strategy for structural studies of an enzymatic mechanism
usually aims at trapping the enzyme both in the ground- and
transition states, using in the latter case inhibitors that mimic
the expected geometry. Co-crystallization with the substrate
analogs becomes a mandatory stage to line out the enzyme ac-
tive site in its stable ground state. For that purpose, analogues
that closely resemble uric acid, the natural substrate were pre-Fig. 1. Weighted electron density map of the active site cavity,
calculated with theoretical phases, contouring is at 1.8 sigma above the
background level. The [S]-ALN molecule is strongly H-bonded to both
the side chains lining the active site and the water molecules that build
a long spine in the access channel. Almost all the polar atoms of
allantoin are involved in its binding scheme.
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high diﬀracting orthorhombic form was obtained. In this
I222 crystal form, the whole functional tetrameric enzyme is
built from the repetition of one monomer (the fourth of the en-
zyme) following the crystallographic 222 symmetry with two
diﬀerent interfaces [3]. The functional tetramer forms a large
16 b-stranded barrel termed Tunneling-fold [1], a new motif
now shared by several other classes of enzymes [10]. The active
site is located at the interface of two subunits. The components
of the reaction center are a molecular tweezers (Arg176, Gln
228), a ‘‘platform’’ (Phe 159) and a ‘‘water holder’’ triad
(Asn 254, Thr 57*, and Lys 10*, from a second subunit).
Numerous water molecules are associated with these residues,
and especially what is expected to be the catalytic water (W1)
maintained in place 3 A˚ above the C4–C5 double bond of the
substrate by the ‘‘water holder’’. Mutations of these residues
invariably result in a drastic loss in the catalytic reaction rate
[11,12].
The catalytic mechanism of uric acid oxidation by UOX is
complex. Many studies have been done and are still on going
to understand how this oxidase works without any cofactor
or metal ion. Isotopic experiments have shown that oxygen
atom from hydrogen peroxide derived from molecular oxygen
and that carbon dioxide derived from the C6 of uric acid [13].
Given the pK value of the four acid groups of uric acid, it is
likely that a dianion, as initially proposed by Bentley and Neu-
berger [13], would be the actual substrate. Which dianion is
eﬀective is presently unclear, the N3,N9 dianion has been ﬁrst
proposed [14,15] but a N3,N7 dianion may be equally advo-
cated [16]. Allantoin is the ultimate product of the reaction.
However, NMR [17] and spectroscopy [18,19] studies sug-
gested that a metastable intermediate, identiﬁed as 5-HIU,
was the real product of the reaction. Other short-life interme-
diates, amongst them a hydroperoxide, between urate dianion
and 5-HIU have been proposed through stopped-ﬂow absor-Fig. 2. (A) Superimposition of the active sites of [S]-ALN/UOX and 8-AZA
water molecules of interest are represented: W1, held by Asn 254 and Thr 57*
W2 in the mean plane of the ligand. In [S]-ALN/UOX, W3 ﬁlls the location o
Gln 228 (also visible in Fig. 1). Water molecules are color coded in red for 8-A
site ligands. [S]-ALN and 8-AZA (equivalent to the initial product) display a s
diﬀerent hydrogen bonding scheme. Cartoons are drawn using PyMol [26], wbance and ﬂuorescence spectroscopy experiments [19,20].
However, according to another mechanism from quantum
mechanistic calculations, no hydroperoxide intermediate needs
to be postulated [16]. Mutagenesis studies in B. subtilis have
shown that a threonine and a lysine (T57 and K10 in A. ﬂavus
UOX numbering, both implicated in the ‘‘water holder’’) play
a role in the catalytic reaction, while the neighbor aspartic acid
D58 does not [11]. The Phe 159, 3.5 A˚ below the planar ligand,
is also of great importance by stacking (and hence stabilizing)
the dianion [12]. Still under investigation is the end of the reac-
tion (step 2 to 3 in Scheme 1). Initially stated as a non-enzy-
matic and spontaneous hydrolysis without implication of
UOX, this last step is now thought accelerated by another en-
zyme not fully characterized [21–23].
3.1. Allantoin in the active site
The Fig. 2 represents the superimposition of the active site
environment in two diﬀerent structures: 8-AZA/UOX vs [S]-
ALN/UOX. All the mandatory partners are represented: the
molecular tweezers (Arg 176 and Gln 228), the triad Asn
254, Thr 57* and Lys 10*, and the platform Phe 159. The
W1 water molecule held by the triad is observed in all the
structures of UOX so far determined [1–3] in a location that
invoke the premises of the hydroxylation step of the reaction.
In all the UOX/inhibitor complexes, the ligand adopt the same
orientation at the same place, a strong indication that urate
would certainly beneﬁt of the same location at the beginning
of the catalysis. Surprisingly, UOX accommodates also [S]-
ALN at the exact location of 8-AZA showing only a slight
rotation (Fig. 2B) about the ﬁve-membered ring. This illus-
trates an unexpected plasticity of the UOX active site as it
can accommodate not only the well known cyclic purine
NH–CO–NH–CO– motif but also open ring compounds like
allantoin. In this complex, all the N and O atoms are involved
in strong polar interactions toward either the protein and/or/UOX. The [S]-ALN ligand is shown in cyan and 8-AZA in grey. Only
(* stands for a symmetry-related subunit) with Lys 10* as a relay, and
f the O(2) atom from 8-AZA and relays the molecular tweezers Arg176/
ZA/UOX and in green for [S]-ALN/UOX. (B). Top view of the active
mall restricted rotation in the plane imposed by Phe-159 stacking and a
ater molecules are color coded like in A.
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a non-symmetric manner, due to the cavity now opened by the
missing six-membered ring in [S]-ALN. To allow correct
hydrogen bonding, Gln 228 now recruits a new water molecule
(W3). This W3 molecule is also observed in the ligand-free
structure [2]. Important to note is the polar interaction be-
tween [S]-ALN and the Thr 57* main chain nitrogen, already
observed in all the high resolution I222 structures with pur-
ine-type inhibitors, and thought to be at the origin of the per-
fect two-fold symmetry of the orthorhombic form. Above the
mean plane of [S]-ALN, the ‘‘water holder’’ triad adopts a
looser conﬁguration compared to the 8-AZA/UOX structure.
The ﬁrst interaction in the triad Asn254–W1–Thr57*–Lys10*
is nearly abolished as distance increases from 2.78 A˚ in 8-
AZA/UOX up to 3.47 A˚ in [S]-ALN/UOX complex, due to a
clear displacement of Asn 254 side chain of about one ang-
stro¨m. However, the W1 molecule, still hydrogen-bonded to
the Thr57*, remains in place for a new reaction. The distance
between Thr57* and Lys10* side chains is also lengthened of
0.35 A˚. Thus only W1 and Thr57* are not spatially aﬀected.
In the structure of UOX without inhibitor [2] and, in a lesser
extend, in UOX from other sources (Bacillus sp. and Arthro-
bacter globiformis, PDB codes: 1J2G, 1VAX, [24,25]), it is al-
ways the Asn 254 side chain the most aﬀected in the diﬀerent
active sites. A superimposition of the residue side chains that
build the active site in the 8-azaxanthin and the allantoin com-
plexes, shows a RMSD of 0.2 A˚ with a maximum of 0.6 A˚ for
Asn 254. The W2 molecule, located in the plane near the N(9)
of 8-azaxanthin, and probably at close distance of the proton-
ated urate N(9), occupies the same position with respect to
allantoin. W2 like W1 is also ready in good place to interact
with the substrate.
3.2. Stereochemical implications
According to the overall geometry of the partners, and espe-
cially W1 above the urate plane, it is plausible that the absolute
conﬁguration of 5-HIU is [S] with the hydroxyl function in ax-
ial position. Up to now, the chirality of 5-HIU has not yet been
determined. Further degradation of [S]5-HIU would logically
drive to [S]-ALN if the molecule stays in a chiral environment.
Hence, to explain the formation of the [S]-ALN/UOX com-
plex, two hypotheses may be formulated at the end of the ﬁrst
step of the reaction: either (i) the 5-HIU is expelled, its hydro-
lysis occurs in solution and the enzyme catch back selectively
the [S] isomer from the racemic [±]-ALN in solution, or (ii)
the two steps ending to [S]-ALN proceed in the active site of
UOX, leading to an optically active [S]-ALN. It is very unli-
kely that the mechanism follows the second hypothesis accord-
ing to the numerous experimental and theoretical evidences
[16–23]. In that context, the recapture of [S]-ALN is the most
probable pathway.4. Conclusion
In the present study, we report an insight of one end state of
urate degradation by UOX. Assuming that 8-AZA position
mimics the location of urate, we have in hands two ground
states of the enzyme. Indeed, nothing can be determined about
the diﬀerent intermediates that several authors have proposed
[15–17,19,20,23]. Because X-ray diﬀraction oﬀers only a staticview of stable conﬁgurations, it is diﬃculty to catch a metasta-
ble intermediate with a short lifetime like 5-HIU. However,
comparisons between these two states show that the recap-
tured ligand in the active site keeps the same orientation with
a rearrangement of the hydrogen bonding around it. This is
also true for the side chains lining the active site. Questions still
remain about the end of the degradation and the role and ori-
gin of the 5-HIU hydrolase [22,23]. Allantoin itself is further
degraded by a speciﬁc enzyme to allantoate, a process that re-
quires [S]-ALN as substrate, not the racemic mixture that
would result from a non-enzymatic hydrolysis of 5-HIU. With
these considerations, 5-HIU hydrolase, although not neces-
sary, becomes an important link to speed up the degradation
chain of urate by selecting the good enantiomer. The present
observation that UOX is able to catch back the end product
with a high aﬃnity reveals unexpected plasticity and confor-
mational adaptation of UOX active site that was not observed
before.
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